Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Immuneering Corporation (IMRX) had Return on Tangible Equity of -6.77% for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-14.96M |
|
-- |
|
-- |
|
$15.38M |
|
$-15.38M |
|
$0.42M |
|
$-14.96M |
|
$-14.96M |
|
$-14.96M |
|
$-14.96M |
|
$-14.96M |
|
$-14.96M |
|
$-15.38M |
|
$-15.21M |
|
39.67M |
|
39.67M |
|
$-0.38 |
|
$-0.38 |
|
| Balance Sheet Financials | |
$229.10M |
|
$0.89M |
|
$11.95M |
|
$241.06M |
|
$9.55M |
|
-- |
|
$3.53M |
|
$13.08M |
|
$227.98M |
|
$220.96M |
|
$227.98M |
|
63.48M |
|
| Cash Flow Statement Financials | |
$-35.50M |
|
$-0.02M |
|
$226.94M |
|
$36.14M |
|
$227.56M |
|
$191.42M |
|
$4.67M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
24.00 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-35.52M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-6.56% |
|
|
Return on Tangible Equity |
-6.77% |
-6.21% |
|
-6.56% |
|
$3.59 |
|
$-0.90 |
|
$-0.90 |
|